TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16612142

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic gels containing ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 36.5‐mM concentration of methyl nicotinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12802750

Group type: EXPERIMENTAL
Intervention: Combination therapy with lamivudine (100 mg daily) and IFN‐alpha‐2b (10 million U 3 times per week for 12 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: IFN‐alpha‐2b monotherapy (10 million U 3 times per week for 12 months)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 49
Study: 10793324

Group type: EXPERIMENTAL
Intervention: Opipramol (200 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 8871411

Group type: EXPERIMENTAL
Intervention: Dismissing adult attachment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoccupied adult attachment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomous adult attachment group
Number of subjects: 0
Study: 1386490

Group type: EXPERIMENTAL
Intervention: Perindopril (4 to 8 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 to 80 mg daily in slow-release form)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both perindopril and nifedipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40
Study: 6526628

Group type: EXPERIMENTAL
Intervention: Single layer technique
Number of subjects: 172

Group type: COMPARATOR
Intervention: Double layer technique
Number of subjects: 172
Study: 30463577

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Syringe lidocaine
Number of subjects: 60
Study: 27809868

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (0.4 mg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 24632753

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 400/100 mg twice a day plus nucleoside reverse transcriptase inhibitors
Number of subjects: 56
Study: 23394476

Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (Merci Retriever or Penumbra System)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (favorable penumbral pattern)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care (favorable penumbral pattern)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (nonpenumbral pattern)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care (nonpenumbral pattern)
Number of subjects: 118
Study: 20719902

Group type: EXPERIMENTAL
Intervention: Baseline BMI (obese III)
Number of subjects: 36941

Group type: EXPERIMENTAL
Intervention: Baseline height
Number of subjects: 36941

Group type: EXPERIMENTAL
Intervention: Baseline weight, waist circumference, hip circumference, waist-to-hip ratio (WHR)
Number of subjects: 36941
Study: 18458278

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 17129904

Group type: EXPERIMENTAL
Intervention: Project LIGHT (seven-session, small-group intervention)
Number of subjects: 99

Group type: COMPARATOR
Intervention: One-session video intervention
Number of subjects: 99
Study: 12614248

Group type: EXPERIMENTAL
Intervention: Doxazosin-GITS
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 52
Study: 11155006

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium (weight-adapted dosing based on body weight)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Heparin sodium (fixed dose of 3,000 IU)
Number of subjects: 1190
Study: 8957719

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin monotherapy
Number of subjects: 55
Study: 1552197

Group type: COMPARATOR
Intervention: Aminoglycoside therapy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 184
Study: 3549878

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 51
Study: 31436359

Group type: EXPERIMENTAL
Intervention: Heat application
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise after heat application
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (routine treatment only)
Number of subjects: 62
Study: 29465560

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 124
Study: 26746195

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 50
Study: 24837863

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) exposure before very preterm birth
Number of subjects: 0
Study: 22717418

Group type: EXPERIMENTAL
Intervention: IRO‐A 1 × 5 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IRO‐A 2 × 5 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IRO‐A 2 × 7.5 mg (fasted)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IRO‐A 2 × 7.5 mg (fed)
Number of subjects: 35

Group type: COMPARATOR
Intervention: IRO 1 × 15 mg (fed)
Number of subjects: 35

Group type: COMPARATOR
Intervention: IRO‐A and IRO tablets (safety profile)
Number of subjects: 35
Study: 20379676

Group type: EXPERIMENTAL
Intervention: Glaze (G)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Polishing discs (Sof-Lex) (Sl)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Porcelain polishing kit (NTI) (Pk)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Porcelain polishing kit (Dialite II) (Di)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diamond polishing paste (Sparkle) (Sp)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Zirconium silicate based cleaning and polishing prophy paste (Zircate) (Zr)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Aluminum oxide polishing paste (Prisma Gloss) (Pg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (C) - no surface treatment
Number of subjects: 55
Study: 18053120

Group type: EXPERIMENTAL
Intervention: 0.0125 mg/kg/d of GH subcutaneously added to standard therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 24
Study: 15632819

Group type: EXPERIMENTAL
Intervention: Left ventricular assist devices
Number of subjects: 129

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 129
Study: 11105542

Group type: EXPERIMENTAL
Intervention: Silicone IOL (Allergan SI40NB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (Alcon Acrysof MA60BM)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 35
Study: 9308144

Group type: EXPERIMENTAL
Intervention: Simulated dive to 375 kPa in a hyperbaric chamber
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control exercise at ambient pressure
Number of subjects: 8
Study: 8476802

Group type: EXPERIMENTAL
Intervention: 45 min incremental oxytocin infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: 15 min incremental oxytocin infusion
Number of subjects: 90
Study: 3774206

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 50 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 100 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30304712

Group type: EXPERIMENTAL
Intervention: Greater injection self-efficacy
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Greater length of the relationship
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Greater relationship communication
Number of subjects: 510
Study: 27277211

Group type: EXPERIMENTAL
Intervention: Low protamine dosing (0.8 protamine-to-heparin ratio; n=49)
Number of subjects: 96

Group type: COMPARATOR
Intervention: High protamine dosing (1.3 protamine-to-heparin ratio; n=47)
Number of subjects: 96
Study: 23196892

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SPA) with 7.5 mg hyperbaric bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA) with Propofol and Fentanyl
Number of subjects: 50
Study: 21446929

Group type: EXPERIMENTAL
Intervention: ST analysis of the fetal ECG (STAN)
Number of subjects: 566

Group type: COMPARATOR
Intervention: CTG only
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: CTG plus ST analysis
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: ST analysis to prevent one case of metabolic acidosis
Number of subjects: 566
Study: 18423809

Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 203

Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 203
Study: 16545254

Group type: EXPERIMENTAL
Intervention: PiKo‐1 device
Number of subjects: 40
Study: 14696681

Group type: EXPERIMENTAL
Intervention: Acupressure at Neiguan (PC-6), Zusanli (ST-36), and Sanyinjiao (SP-6) for 3 minutes, twice a day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham acupressure for 3 minutes, twice a day
Number of subjects: 41
Study: 11232980

Group type: EXPERIMENTAL
Intervention: CDDP-based therapy group (CB Group, CDDP+VDS+tegafur+OK-432 or CDDP+OK-432+mediastinal irradiation)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Immunochemotherapy group (IC Group, tegafur+OK-432)
Number of subjects: 94
Study: 9316524

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TD‐NTG) 0.2 to 0.4 mg/h
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TD‐NTG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8468440

Group type: COMPARATOR
Intervention: moclobemide, 450 mg/day
Number of subjects: 12
Study: 3545141

Group type: EXPERIMENTAL
Intervention: Ketoconazole, 200 mg via the gastrointestinal tract daily for 21 days or until one week after discharge from the SICU.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31506808

Group type: EXPERIMENTAL
Intervention: Trans-obturator vaginal mesh (TVM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Anterior colporrhaphy (native tissue repair)
Number of subjects: 147
Study: 29702246

Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Routine antenatal care (Control)
Number of subjects: 43
Study: 26526926

Group type: EXPERIMENTAL
Intervention: Fungisome™ 5 mg/kg daily for 2 days (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fungisome™ 7.5 mg/kg daily for 2 days (Group B)
Number of subjects: 120
Study: 25436051

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 44
Study: 22718708

Group type: EXPERIMENTAL
Intervention: Resource-enhancing group intervention (4 half-day sessions)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Comparison group (literature package)
Number of subjects: 566
Study: 20009936

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 88
Study: 18418964

Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Gantang comprehensive therapeutic program (FHGP)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional TCM and Western medicine therapeutic program
Number of subjects: 142
Study: 20544413

Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention Program (PIP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 115
Study: 16142731

Group type: EXPERIMENTAL
Intervention: Management-focused intervention addressing hazardous substance exposures over 16 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (prevalent practice, more downstream, worker-focused)
Number of subjects: 15
Study: 12145058

Group type: EXPERIMENTAL
Intervention: Tizanidine (4 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 52
Study: 9926097

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Behavioural stress management
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment waiting list control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cognitive therapy and Behavioural stress management
Number of subjects: 48
Study: 8139083

Group type: EXPERIMENTAL
Intervention: 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: 160 mg/d of tacrine for the last 12 weeks
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Tacrine treatment
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 3370062

Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 6
Study: 29700058

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: History of AF
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Female sex (after propensity score adjustment)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Prior direct current cardioversion
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 750
Study: 27759930

Group type: EXPERIMENTAL
Intervention: Intermittent Cyclical Etidronate Therapy
Number of subjects: 0
Study: 24321442

Group type: EXPERIMENTAL
Intervention: Medial KOA group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 22986600

Group type: EXPERIMENTAL
Intervention: ICP monitor group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imaging and clinical examination group
Number of subjects: 0
Study: 20732948

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13 toddler dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study: 18560843

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 926

Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 926
Study: 16879437

Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5/15 mg once daily
Number of subjects: 716
Study: 12947359

Group type: EXPERIMENTAL
Intervention: Ximelagatran (36 mg bid)
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted to INR 2.0-3.0)
Number of subjects: 7329
Study: 10374139

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) including all items
Number of subjects: 105

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 105
Study: 8909936

Group type: EXPERIMENTAL
Intervention: 3 g corn peptide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5 g corn peptide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no corn peptide)
Number of subjects: 20
Study: 1867581

Group type: EXPERIMENTAL
Intervention: Nimorazole 2 g single dose (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nimorazole 1 g per day for 3 days (Group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nimorazole 1 g per day for 7 days (Group III)
Number of subjects: 90
Study: 6817770

Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam 2.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupropion 100 mg + Diazepam 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupropion 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam 2.5 mg and 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupropion 100 mg + Diazepam 2.5 mg and 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupropion alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 12
Study: 30335131

Group type: EXPERIMENTAL
Intervention: PMCb (paclitaxel plus nonpegylated liposomal doxorubicin plus carboplatin)
Number of subjects: 315

Group type: COMPARATOR
Intervention: PM (paclitaxel plus nonpegylated liposomal doxorubicin)
Number of subjects: 315
Study: 26936333

Group type: EXPERIMENTAL
Intervention: Low-glycemic index (low-GI) diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: High-fiber (HF) diet
Number of subjects: 59
Study: 25876339

Group type: EXPERIMENTAL
Intervention: Acupuncture (needling technique for benefiting qi, promoting blood circulation, regulating mind and improving intelligence)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Donepezil (5 mg tablet once every night for 4 weeks, increased to 10 mg tablet after 4 weeks)
Number of subjects: 141
Study: 22901981

Group type: EXPERIMENTAL
Intervention: Induction of Labor (IoL)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Expectant Management (EM)
Number of subjects: 195
Study: 19891804

Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behaviour therapy (CBT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 63
Study: 18461182

Group type: EXPERIMENTAL
Intervention: Surgical face masks
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Hand hygiene
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control
Number of subjects: 198
Study: 16325036

Group type: EXPERIMENTAL
Intervention: Pravastatin (statin group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adult Treatment Panel-III diet therapy (diet group)
Number of subjects: 60
Study: 15486892

Group type: EXPERIMENTAL
Intervention: Serum pancreatic isoamylases in children with PBM preoperatively
Number of subjects: 12

Group type: COMPARATOR
Intervention: Serum pancreatic isoamylases in normal controls
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Serum pancreatic isoamylases in pigs preoperatively
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Serum pancreatic isoamylases in pigs 30 and 60 days after model establishment
Number of subjects: 12
Study: 11120421

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 77
Study: 9401590

Group type: EXPERIMENTAL
Intervention: Two-leg exercise for 30 min at 60% of two-leg VO2 max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: One-leg exercise for 30 min at 60% of one-leg VO2 max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: One-leg exercise (one-leg TW) at 60% of one-leg VO2 max with total work equal to two-leg trial (duration approximately 50 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting control
Number of subjects: 12
Study: 8445203

Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3510214

Group type: EXPERIMENTAL
Intervention: Distal metatarsal osteotomy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Keller's arthroplasty
Number of subjects: 33
Study: 30500142

Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 1.0%
Number of subjects: 885

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 885
Study: 27250984

Group type: EXPERIMENTAL
Intervention: Live visual and auditory feedback on time under tension using BandCizer™ and an iPad during a 6-week intervention period.
Number of subjects: 40

Group type: COMPARATOR
Intervention: No feedback on time under tension during a 6-week intervention period.
Number of subjects: 40
Study: 24996573

Group type: EXPERIMENTAL
Intervention: 1:1:1 transfusion ratio (plasma, platelets, and red blood cells)
Number of subjects: 680

Group type: COMPARATOR
Intervention: 1:1:2 transfusion ratio (plasma, platelets, and red blood cells)
Number of subjects: 680
Study: 21879233

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both PMR and Control groups
Number of subjects: 25
Study: 20509796

Group type: EXPERIMENTAL
Intervention: Narrowband Imaging TUR (NBI TUR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard TUR
Number of subjects: 62
Study: 17973267

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus dexamethasone (Cy-Dex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and dexamethasone (VAD)
Number of subjects: 0
Study: 15999255

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20% albumin solution
Number of subjects: 16
Study: 14557446

Group type: EXPERIMENTAL
Intervention: Flutamide-metformin (flutamide 62.5 mg/d) in OC- teenagers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flutamide-metformin added to gestodene-containing OC in OC+ women
Number of subjects: 45
Study: 11783156

Group type: EXPERIMENTAL
Intervention: Shuxinsu capsule (SXSC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Yixin oral liquid (YXOL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Shuxinsu capsule (SXSC) and openly treated group (OTG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (OTG)
Number of subjects: 150
Study: 7878166

Group type: EXPERIMENTAL
Intervention: Common and distinctive stimulus components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common stimulus components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive stimulus components
Number of subjects: 0
Study: 2196623

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine 60 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (various doses)
Number of subjects: 0
Study: 354472

Group type: EXPERIMENTAL
Intervention: Carticaine 2% without adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prilocaine 2% without adrenaline
Number of subjects: 0
Study: 28808791

Group type: EXPERIMENTAL
Intervention: EVOO (25 mL daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (25 mL soybean oil daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EVOO
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41